A1 Refereed original research article in a scientific journal

A plasma metabolite score of three eicosanoids predicts incident type 2 diabetes: a prospective study in three independent cohorts




AuthorsTuomisto Karolina, Palmu Joonatan, Long Tao, Watrous Jeramie D, Mercader Kysha, Lagerborg Kim A, Andres Allen, Salmi Marko, Jalkanen Sirpa, Vasan Ramachandran S, Inouye Michael, Havulinna Aki S, Tuomilehto Jaakko, Jousilahti Pekka, Niiranen Teemu J, Cheng Susan, Jain Mohit, Salomaa Veikko

PublisherBMJ PUBLISHING GROUP

Publication year2022

JournalBMJ open diabetes research and care

Journal acronymBMJ OPEN DIAB RES CA

Article number e002519

Volume10

Issue2

Number of pages9

eISSN2052-4897

DOIhttps://doi.org/10.1136/bmjdrc-2021-002519

Web address https://drc.bmj.com/content/10/2/e002519

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/175276091


Abstract

Introduction Peptide markers of inflammation have been associated with the development of type 2 diabetes. The role of upstream, lipid-derived mediators of inflammation such as eicosanoids, remains less clear. The aim of this study was to examine whether eicosanoids are associated with incident type 2 diabetes.

Research design & methods In the FINRISK (Finnish Cardiovascular Risk Study) 2002 study, a population-based sample of Finnish men and women aged 25-74 years, we used directed, non-targeted liquid chromatography-mass spectrometry to identify 545 eicosanoids and related oxylipins in the participants' plasma samples (n=8292). We used multivariable-adjusted Cox regression to examine associations between eicosanoids and incident type 2 diabetes. The significant independent findings were replicated in the Framingham Heart Study (FHS, n=2886) and Dietary, Lifestyle and Genetic determinants of Obesity and Metabolic syndrome (DILGOM) 2007 (n=3905). Together, these three cohorts had 1070 cases of incident type 2 diabetes.

Results In the FINRISK 2002 cohort, 76 eicosanoids were associated individually with incident type 2 diabetes. We identified three eicosanoids independently associated with incident type 2 diabetes using stepwise Cox regression with forward selection and a Bonferroni-corrected inclusion threshold. A three-eicosanoid risk score produced an HR of 1.56 (95% CI 1.41 to 1.72) per 1 SD increment for risk of incident diabetes. The HR for comparing the top quartile with the lowest was 2.80 (95% CI 2.53 to 3.07). In the replication analyses, the three-eicosanoid risk score was significant in FHS (HR 1.24 (95% CI 1.10 to 1.39, p<0.001)) and directionally consistent in DILGOM (HR 1.12 (95% CI 0.99 to 1.27, p=0.07)). Meta-analysis of the three cohorts yielded a pooled HR of 1.31 (95% CI 1.05 to 1.56).

Conclusions Plasma eicosanoid profiles predict incident type 2 diabetes and the clearest signals replicate in three independent cohorts. Our findings give new information on the biology underlying type 2 diabetes and suggest opportunities for early identification of people at risk.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 23:21